Aluminum localization in bone from hemodialyzed patients: relationship to matrix mineralization.
It has been suggested that in uremic bone, aluminum interferes with normal mineralization. Aluminum content and aluminum localization were studied in iliac crest biopsies of two groups of patients on regular hemodialysis; one group had histologic osteomalacia, and little or no bone resorption (group 1); the other, osteitis fibrosa and no mineralization defect (group 2). Group 1 patients had significantly higher plasma aluminum concentrations than those of group 2. No difference was found in bone aluminum content, which was above normal in both groups. In the bone samples of the osteomalacic subjects, aluminum was mainly localized at the limit between osteoid and calcified tissue, the site where the bone mineral is normally first deposited. Osteomalacia could not be related to hypocalcemia or to phosphate depletion. Active vitamin D derivatives (25-hydroxycholecalciferol and 1alpha-hydroxycholecalciferol) failed to prevent or to improve the bone disease. In the bone samples of group 2 subjects, aluminum could not be localized by the methods used, except in the two cases with greatly elevated bone aluminum, where it was mainly localized on cement lines. In group 2 subjects, immunoreactive parathyroid hormone plasma concentration, osteoclast surface, and marrow fibrosis were significantly higher than they were in group 1 subjects. It is concluded that in bone from uremic patients on regular dialysis, aluminum can induce a particular form of osteomalacia, resistant to the vitamin D active derivatives. The bone disease is only observed in the absence of severe secondary hyperparathyroidism. This suggests that parathyroid hormone may be involved in the development of the aluminum-induced mineralization defect.
D000328:Adult; D000535:Aluminum / Q000032:analysis* / Q000506:poisoning; D001706:Biopsy; D001862:Bone Resorption; D001842:Bone and Bones / Q000032:analysis / Q000378:metabolism* / Q000473:pathology*; D005260:Female; D005357:Fibrous Dysplasia of Bone / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D008903:Minerals / Q000378:metabolism*; D010018:Osteomalacia / Q000188:drug therapy / Q000209:etiology* / Q000378:metabolism; D006435:Renal Dialysis / Q000009:adverse effects; D014511:Uremia / Q000378:metabolism / Q000628:therapy; D014807:Vitamin D / Q000627:therapeutic use
D008903:Minerals; D014807:Vitamin D; D000535:Aluminum